Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.36 |
| ▸ | CDC25B | P30305 | 8/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13667662 | 0.88 | PTPN1 (0.37) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL19412708 | 0.87 | PTPN1 (0.34) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL17106669 | 0.87 | PTPN1 (0.34) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL27086454 | 0.86 | PDE2A (0.37) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL12243141 | 0.86 | PDE2A (0.37) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL12393373 | 0.86 | PDE2A (0.37) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL28405132 | 0.86 | BCHE (0.38) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL31063739 | 0.86 | PDE2A (0.37) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL28404433 | 0.86 | PTPN1 (0.33) | PTPN1CDC25BHTR1ABCHEPTPN2 | |
| SCHEMBL19412421 | 0.84 | TSHR (0.32) | TSHRCASP3RAB9ASENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-19 | — | — | US | disclosed |
| EP-4219496-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-111233869-B | Novel compound for preparing Rudexilvir key intermediate and preparation method thereof | 杭州新博思生物医药有限公司 | 2022-09-16 | — | — | CN | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| EP-3956341-A1 | CD73 INHIBITORS | Bioardis LLC (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3341368-B1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
| CN-111233869-A | Novel compound for preparing Rudexilvir key intermediate and preparation method thereof | 杭州新博思生物医药有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2017032840-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| EP-3122752-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148746-A1 | 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015143712-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PTPN1 4059/4885CDC25B 2654/4885HTR1A 4217/4885 |
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | PTPN1 3398/4885CDC25B 1008/4885HTR1A 4006/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | PTPN1 4155/4885CDC25B 2539/4885HTR1A 4169/4885 |
| US-20230330127-A1 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | PTPN1 3799/4885CDC25B 2171/4885HTR1A 3435/4885 |
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PTPN1 4059/4885CDC25B 2654/4885HTR1A 4217/4885 |
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | PTPN1 922/4885CDC25B 2277/4885HTR1A 2118/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | PTPN1 3398/4885CDC25B 1008/4885HTR1A 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.